{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:58:47Z","timestamp":1788580727529,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clml.2024.12.010","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T16:54:12Z","timestamp":1735059252000},"page":"357-364.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8902-4162","authenticated-orcid":false,"given":"Koen M.","family":"Klomberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Gelderloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde A.M.","family":"Kooistra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin A.","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried W.H.","family":"Roeloffzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter J.","family":"Plattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2024.12.010_bib0001","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.12.010_bib0002","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.12.010_bib0003","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.12.010_bib0004","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.12.010_bib0005","first-page":"33","article-title":"Het multipel myeloom in Nederland, 2014-2017. Landelijk rapport van het hemato-oncologie register van de Nederlandse Kankerregistratie","author":"Brink","year":"2020","journal-title":"The Netherlands: integraal kanker centrum Nederland"},{"issue":"14","key":"10.1016\/j.clml.2024.12.010_bib0006","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2024.12.010_bib0007","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.clml.2024.12.010_bib0008","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.12.010_bib0009","doi-asserted-by":"crossref","unstructured":"Gulla A., Anderson K.C. Multiple myeloma: the revolution of current therapy and a glance into future. Haematologica 2020;105(10):2358-2367. doi:10.3324\/haematol.2020.247015","DOI":"10.3324\/haematol.2020.247015"},{"issue":"7","key":"10.1016\/j.clml.2024.12.010_bib0010","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.12.010_bib0011","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","article-title":"Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE","volume":"35","author":"Goldschmidt","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2024.12.010_bib0012","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.12.010_bib0013","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.12.010_bib0014","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.13835","article-title":"Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis","volume":"109","author":"Spicka","year":"2022","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2024.12.010_bib0015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2024.12.010_bib0016","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10214","key":"10.1016\/j.clml.2024.12.010_bib0017","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.clml.2024.12.010_bib0018","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.12.010_bib0019","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-018-0583-7","volume":"11","author":"Dimopoulos","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.12.010_bib0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2024.12.010_bib0021","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.clml.2024.12.010_bib0022","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.12.010_bib0023","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of Daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2024.12.010_bib0024","doi-asserted-by":"crossref","unstructured":"Rajkumar S.V., Harousseau J.L., Durie B., et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691-4695. doi:10.1182\/blood-2010-10-299487","DOI":"10.1182\/blood-2010-10-299487"},{"issue":"4","key":"10.1016\/j.clml.2024.12.010_bib0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41409-022-01592-y","article-title":"Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT","volume":"57","author":"Drozd-Soko\u0142owska","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2024.12.010_bib0026","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41375-020-1005-8","article-title":"Salvage second transplantation in relapsed multiple myeloma","volume":"35","author":"Dhakal","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.12.010_bib0027","doi-asserted-by":"crossref","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.clml.2024.12.010_bib0028","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2024.12.010_bib0029","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:33:15Z","timestamp":1751398395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024024492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2152265024024492"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}